Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF in Recurrent Implantation Failure
NCT01715974Phase 3Unknown
- Sponsor
- Centre for Endocrinology and Reproductive Medicine
- Start
- Dec 2017
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of sargramostim in Recurrent Implantation Failure (RIF), sponsored by Centre for Endocrinology and Reproductive Medicine. Status: unknown.
02
Drugs
sargramostim
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT01715974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01715974.